As per the agreement ART has granted Nihon a non-exclusive and restricted right and license to use, sell and sub-license its proprietary signal-averaging electrocardiography (SAECG) software, Predictor, customised for exclusive use in Nihon’s electrocardiogram and other ECG-related products.
ART has claimed that it’s patented Predictor software filters and analyses the data to present the signal-averaged ECG for interpretation by a cardiologist.
James Rouse, president and CEO of ART, said: “We are very pleased to announce that Nihon is the first OEM to license our customisable Predictor SAECG analysis software. This agreement, which has an initial term of five years, is the result of a long and cooperative development project between our two companies. Signal-averaged electrocardiographic analysis is a very valuable risk stratification tool for electrophysiologists and cardiologists in the management of post myocardial infarction patients.
“ART’s Predictor software is considered by the American College of Cardiology and the American Heart Association to be the ‘Gold Standard’ in signal-averaged electrocardiography analysis. We are very proud that Predictor and the ART name are now associated with Nihon. Fees associated with this agreement are expected to contribute to revenues beginning in the second quarter of 2010.”